Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Form 4 filing for Standard BioTools Inc. (LAB) dated 24 June 2025 discloses equity compensation granted to board member Frank Witney on 20 June 2025.
Restricted Stock Units (RSUs): Witney received 94,592 RSUs at no cost. The award vests in full on the earlier of 20 June 2026 or one day prior to the company’s next annual shareholder meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting. After the grant, the director’s direct holdings rise to 210,862 shares; an additional 4,225 shares are held indirectly through a family trust.
Stock Option: He also received a non-qualified option for 125,660 shares with a strike price of $1.05. The option vests in twelve equal monthly installments starting 20 July 2025 and expires 20 June 2035. The filing reports no disposals and no cash paid for the RSUs; any cash impact would occur only if the option is exercised.
The transaction reflects a routine, service-based compensation grant rather than an open-market purchase, aligning director incentives with shareholder value but producing no immediate effect on cash flow or operations. If fully vested and exercised, the awards could increase the company’s outstanding share count by up to 220,252 shares, but the filing provides no data to assess relative dilution.
Standard BioTools Inc. (Nasdaq: LAB) filed an 8-K reporting the outcomes of its 2025 Annual Meeting held on 18 June 2025. Shareholder turnout was high, with 326,864,517 votes cast, representing approximately 86.06% of the 379,822,268 shares outstanding on the 25 April 2025 record date.
The meeting covered four key proposals, all of which passed with comfortable majorities:
- Election of two Class III directors: Kathy Hibbs (96.2% support) and Frank Witney, Ph.D. (97.9% support) were elected to serve until the 2028 annual meeting.
- Say-on-Pay: Executive compensation for FY 2024 received 97.0% shareholder approval (241.1 million FOR vs. 4.0 million AGAINST).
- Auditor ratification: PricewaterhouseCoopers LLP was re-appointed for FY 2025 with 98.8% support (322.9 million FOR).
- Equity Incentive Plan amendment: Shareholders approved increasing the Amended and Restated 2011 Equity Incentive Plan share reserve by 17.4 million shares (223.4 million FOR, 19.6 million AGAINST).
The additional share reserve expands the pool available for future equity grants to employees and directors. Full plan details are provided in Exhibit 10.1, with prior discussion in the company’s 30 April 2025 proxy statement.
No other material transactions, financial results or leadership changes were disclosed in this filing.